Changeflow GovPing Pharma & Drug Safety Multimeric T-Cell Modulatory Polypeptides and M...
Routine Notice Added Final

Multimeric T-Cell Modulatory Polypeptides and Methods of Use Thereof

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO has published patent application US20260097127A1 for multimeric T-cell modulatory polypeptides comprising immunomodulatory polypeptides and epitope-presenting Wilms tumor peptides. The application, filed October 6, 2025, names Saso Cemerski, Rodolfo J. Chaparro, Ronald D. Seidel III, and John F. Ross as inventors. The published application covers methods for modulating T-cell activity and immune responses using the disclosed polypeptides.

What changed

The USPTO has published a patent application for multimeric T-cell modulatory polypeptides that combine immunomodulatory polypeptides with epitope-presenting Wilms tumor peptides. The application covers compositions and methods for modulating T-cell activity and immune responses in individuals.

For pharmaceutical and biotechnology companies, this published application represents prior art that may affect freedom-to-operate assessments for competing T-cell modulation technologies. Parties developing similar immunomodulatory or cancer immunotherapy approaches should review the claims to evaluate potential overlap with their own R&D programs.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 12, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

Multimeric T-Cell Modulatory Polypeptides and Methods of Use Thereof

Application US20260097127A1 Kind: A1 Apr 09, 2026

Inventors

Saso Cemerski, Rodolfo J. Chaparro, Ronald D. Seidel, III, John F. Ross

Abstract

The present disclosure provides T-cell modulatory multimeric polypeptides that comprise an immunomodulatory polypeptide and that comprise an epitope-presenting Wilms tumor peptide. A T-cell modulatory multimeric polypeptide is useful for modulating the activity of a T cell, and for modulating an immune response in an individual.

CPC Classifications

A61K 47/646 A61K 39/001114 A61K 39/001153 A61K 47/642 A61K 47/6425 C07K 2319/30

Filing Date

2025-10-06

Application No.

19350474

View original document →

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260097127A1

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application publication Biotechnology research Immunotherapy development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Medical Devices

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!